Peptides.

Why sequence and structure matter

Peptides and proteins are made from amino acids. Their effects also depend on their three-dimensional shape and surroundings. Changing the sequence or chemically modifying it can change where it binds, how long it lasts, where it travels or how the immune system responds.

A shared peptide name does not prove two products are equivalent. Comparing them can require tests of their identity, biological activity and absorption, as well as clinical evidence; the exact requirements depend on the product and regulatory route. See research-peptide quality and handling and travelling with medicines and supplements.1213

From mechanism to medicine

Different peptides can activate or block receptors, resemble hormones, act on enzymes or carry another treatment. Cell and animal studies help investigate their targets and effects. Studies in people must then examine how the product behaves in the body, whether people tolerate it and what benefits and harms occur. A finding at one stage does not guarantee success at the next.

Explore elamipretide (SS-31), its rare-disease approval and the limits of broader claims.645

Delivery and biological fate

Many peptides break down easily in the body or do not cross membranes well. Researchers therefore study how a product is made, absorbed, distributed and broken down, and how well people tolerate the way it is given.

For example, the FDA label says Rybelsus semaglutide tablets use an absorption enhancer called SNAC. They are absorbed mainly in the stomach; the estimated proportion reaching the bloodstream for that formulation is about 0.4% to 1%. An injection, inhaled product or different tablet can produce different exposure. A laboratory finding does not establish the identity, purity or delivery of a product sold online.6714

Manufacturing is part of the claim

Sequence confirmation is only one part of quality. Impurities, aggregates, higher-order structure, potency, sterility and stability may affect exposure and immune responses. FDA’s draft clinical-pharmacology guidance highlights hepatic impairment, interactions, QTc risk and immunogenicity topics for peptide development; it is non-binding guidance for sponsors, not evidence that a product is safe or effective. EMA’s synthetic-peptide guideline addresses manufacture, characterisation and analytical control; these frameworks do not show that every marketed or investigational peptide works. In 2026, FDA issued revised draft product-specific recommendations for certain generic peptides covering, among other topics, impurities, higher-order structure, biological activity and immune-response testing. Their scope is the named proposed generics; they do not mean every peptide requires the same studies.6813

Dose is not a portable number

A dose beside a peptide name does not tell you how much reaches the body. Sequence, form, route, absorption enhancers, injection site and release pattern can all matter. Approved oral semaglutide uses an enhancer called SNAC and has low absorption specific to that formulation. Its label cannot tell you how an injected, compounded or research product will be absorbed. Compare the exact product and route, measurements in the body and people studied.1467

An evidence contrast, not an endorsement

Tirzepatide, retatrutide and BPC-157 illustrate the range. One has regulator-reviewed products and large clinical trials for defined uses. Another remains investigational. Another has mostly laboratory and animal evidence and limited human data. Approval of one peptide does not validate another. For another research question, see MOTS-c and exercise research.9101112

Four evidence gates

For a peptide claim, ask four questions. First, what is the exact substance and its structure? Second, what is known about the product’s identity, purity, strength, impurities, sterility and stability? Third, how much reaches the body and how is it absorbed and cleared? Fourth, what benefits and harms were measured in people, compared with what, and for how long?

The precise evidence needed depends on the product, use and regulatory route. Sponsor guidance does not itself prove a product works. A biological marker, animal result or small uncontrolled study cannot fill every evidence gap.12678

Apply the gates to three examples

Tirzepatide illustrates a peptide with regulator-reviewed products and substantial clinical programmes for defined indications; those records still apply to named products and populations. Retatrutide remains an investigational programme: historical trials and sponsor updates should be kept separate from any authorisation claim. BPC-157 illustrates a thinner human evidence base alongside unresolved product-quality and regulatory questions. A policy or enforcement document about specified compounding is not an FDA approval or evidence of effectiveness. These examples show why one peptide’s evidence cannot validate another peptide sold under the same category label.91011124

Five questions for a peptide claim

What is the exact substance, modification, product form and way it is taken? What evidence comes from cells, animals and people? How were the product’s identity, purity, strength and stability checked? What benefits, harms and follow-up were reported? Is the claim about an approved, experimental, unapproved or compounded product—and in which country?678

U.S. compounding policy: a narrow interim position

In October 2026 HHS published a draft interim enforcement-discretion policy covering specified forms of BPC-157, TB-500, KPV, epitalon, MOTS-c and Semax in section 503A compounding. Its Appendix B identifies the chemical form and routes addressed for each peptide; the policy also describes conditions including a patient-specific prescription, ingredient characterization and a single active ingredient. It is a statement of enforcement intent, not FDA approval or proof of safety or effectiveness; it does not establish the legality or quality of an online vial or a multi-ingredient stack. Read the peptide overview and the linked HHS policy for the specific conditions. Checked 5 November 2026. For a dated explanation of the six substances, conditions and separate 2027 meeting, read the US policy guide.15

What FDA plans to review in 2027

FDA says it plans to convene its Pharmacy Compounding Advisory Committee before the end of February 2027 to discuss GHK-Cu, cathelicidin LL-37, dihexa acetate, melanotan II and pegylated mechano growth factor for possible inclusion on the section 503A bulk substances list. As checked on 5 November 2026, FDA says the meeting time and location are to be scheduled. The committee gives non-binding advice: discussion does not mean inclusion, FDA approval, proven benefit, or that the HHS interim policy will be extended to these substances.16